 |
Video: What is a Stock Split?
|
 |
| Dogwood Therapeutics, Inc., formerly Virios Therapeutics, Inc., is focused on the clinical development of three assets, Halneuron, IMC-1, and IMC-2. Halneuron is in Phase 2b development as a non-opioid, Nav 1.7 inhibitor, to treat the neuropathic pain associated with chemotherapy treatment. Halneuron is an injectable formulation of Tetrodotoxin, a novel small molecule with action exclusively on the peripheral nervous system. IMC-2 (valacyclovir + celecoxib) is in Phase 2 development as a combination antiviral treatment for Long-COVID (LC). IMC-1 (famciclovir (FM) + celecoxib) is Phase 3 development ready as a combination antiviral treatment for FM. According to our DWTX split history records, Dogwood Therapeutics has had 1 split. | |
 |

Dogwood Therapeutics (DWTX) has 1 split in our DWTX split history database. The split for DWTX took place on October 09, 2024. This was a 1 for 25 reverse split, meaning for each 25 shares of DWTX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 40 share position following the split.
When a company such as Dogwood Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the DWTX split history from start to finish, an original position size of 1000 shares would have turned into 40 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Dogwood Therapeutics shares, starting with a $10,000 purchase of DWTX, presented on a split-history-adjusted basis factoring in the complete DWTX split history.

Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
12/18/2020 |
|
| End date: |
11/18/2025 |
|
| Start price/share: |
$260.00 |
|
| End price/share: |
$6.15 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-97.63% |
|
| Average Annual Total Return: |
-53.28% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$236.47 |
|
| Years: |
4.92 |
|
|
 |
| Date |
Ratio |
| 10/09/2024 | 1 for 25 |
|
 |